TILT-123/TIL Combo Appears Safe and Feasible in Metastatic Melanoma
Source: Targeted Oncology, March 2024
When given alone or with tumor infiltrating lymphocyte therapy, TILT-123 given intravenously or intratumorally is safe and feasible for patients with advanced metastatic melanoma.
TILT-123 treatment alone or in combination with tumor infiltrating lymphocyte (TIL) therapy administered intravenously or intratumorally is safe and feasible for patients with advanced metastatic melanoma, according to data from a phase trial (NCT04217473) presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress . The study data showed that no dose-limiting toxicities were observed.
Treatment with the oncolytic adenovirus in combination with TIL therapy resulted in 3 grade 3/4 adverse events (AEs) related to TILT-123 and 5 related to TIL therapy, although no AEs were considered dose limiting; however, 4 serious AEs were related to TILT-123 , including fever (n = 3) and infection in the injected tumor (n = 1).